ARTIVION INC (AORT) Stock Fundamental Analysis
NYSE:AORT - New York Stock Exchange, Inc. - US2289031005 - Common Stock - Currency: USD
Taking everything into account, AORT scores 4 out of 10 in our fundamental rating. AORT was compared to 187 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of AORT get a neutral evaluation. Nothing too spectacular is happening here. While showing a medium growth rate, AORT is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
AORT had negative earnings in the past year.
AORT had a positive operating cash flow in the past year.
In the past 5 years AORT always reported negative net income.
In multiple years AORT reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -2.70%, AORT is in the better half of the industry, outperforming 68.45% of the companies in the same industry.
With a decent Return On Equity value of -7.26%, AORT is doing good in the industry, outperforming 69.52% of the companies in the same industry.
AORT's Return On Invested Capital of 2.26% is fine compared to the rest of the industry. AORT outperforms 69.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.7% | ||
| ROE | -7.26% | ||
| ROIC | 2.26% |
ROA(3y)-2.68%
ROA(5y)-2.4%
ROE(3y)-7.46%
ROE(5y)-6.47%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Operating Margin, with a value of 5.41%, AORT is in the better half of the industry, outperforming 71.66% of the companies in the same industry.
AORT's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 63.94%, AORT is in the better half of the industry, outperforming 65.78% of the companies in the same industry.
AORT's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.41% | ||
| PM (TTM) | N/A | ||
| GM | 63.94% |
OM growth 3Y31.35%
OM growth 5Y5.5%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.05%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
AORT has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for AORT has been increased compared to 1 year ago.
AORT has more shares outstanding than it did 5 years ago.
The debt/assets ratio for AORT is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.40 indicates that AORT is not a great score, but indicates only limited risk for bankruptcy at the moment.
AORT has a better Altman-Z score (2.40) than 62.03% of its industry peers.
AORT has a Debt/Equity ratio of 1.08. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of AORT (1.08) is worse than 79.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.08 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.4 |
ROIC/WACC0.27
WACC8.51%
2.3 Liquidity
A Current Ratio of 5.53 indicates that AORT has no problem at all paying its short term obligations.
With a decent Current ratio value of 5.53, AORT is doing good in the industry, outperforming 79.68% of the companies in the same industry.
AORT has a Quick Ratio of 3.95. This indicates that AORT is financially healthy and has no problem in meeting its short term obligations.
AORT's Quick ratio of 3.95 is fine compared to the rest of the industry. AORT outperforms 71.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.53 | ||
| Quick Ratio | 3.95 |
3. Growth
3.1 Past
The earnings per share for AORT have decreased strongly by -42.86% in the last year.
AORT shows a small growth in Revenue. In the last year, the Revenue has grown by 5.94%.
AORT shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.06% yearly.
EPS 1Y (TTM)-42.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-116.67%
Revenue 1Y (TTM)5.94%
Revenue growth 3Y9.14%
Revenue growth 5Y7.06%
Sales Q2Q%1.59%
3.2 Future
The Earnings Per Share is expected to grow by 46.07% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 11.26% on average over the next years. This is quite good.
EPS Next Y126.09%
EPS Next 2Y75.18%
EPS Next 3Y52.55%
EPS Next 5Y46.07%
Revenue Next Year9.03%
Revenue Next 2Y9.83%
Revenue Next 3Y10.38%
Revenue Next 5Y11.26%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
AORT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 66.97, the valuation of AORT can be described as expensive.
Based on the Price/Forward Earnings ratio, AORT is valued a bit cheaper than the industry average as 66.31% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.44, AORT is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 66.97 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AORT is valued a bit cheaper than the industry average as 68.98% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 35.29 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
AORT's earnings are expected to grow with 52.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y75.18%
EPS Next 3Y52.55%
5. Dividend
5.1 Amount
No dividends for AORT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:AORT (7/21/2025, 12:09:34 PM)
30.78
+0.29 (+0.95%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners90.63%
Inst Owner ChangeN/A
Ins Owners5.01%
Ins Owner Change11.86%
Market Cap1.31B
Analysts86.15
Price Target33.37 (8.41%)
Short Float %3.78%
Short Ratio3.35
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-222.77%
Min EPS beat(2)-537.25%
Max EPS beat(2)91.71%
EPS beat(4)2
Avg EPS beat(4)-133.26%
Min EPS beat(4)-537.25%
Max EPS beat(4)91.71%
EPS beat(8)5
Avg EPS beat(8)-81.69%
EPS beat(12)8
Avg EPS beat(12)-43.69%
EPS beat(16)10
Avg EPS beat(16)-60.45%
Revenue beat(2)1
Avg Revenue beat(2)-1.61%
Min Revenue beat(2)-5.37%
Max Revenue beat(2)2.16%
Revenue beat(4)1
Avg Revenue beat(4)-1.43%
Min Revenue beat(4)-5.37%
Max Revenue beat(4)2.16%
Revenue beat(8)5
Avg Revenue beat(8)0.88%
Revenue beat(12)7
Avg Revenue beat(12)0.57%
Revenue beat(16)10
Avg Revenue beat(16)6.83%
PT rev (1m)1.18%
PT rev (3m)1.18%
EPS NQ rev (1m)-28.83%
EPS NQ rev (3m)-356.89%
EPS NY rev (1m)-1.5%
EPS NY rev (3m)559.87%
Revenue NQ rev (1m)0.12%
Revenue NQ rev (3m)0.49%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)0.89%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 66.97 | ||
| P/S | 3.37 | ||
| P/FCF | N/A | ||
| P/OCF | 121.97 | ||
| P/B | 4.47 | ||
| P/tB | N/A | ||
| EV/EBITDA | 35.29 |
EPS(TTM)-0.5
EYN/A
EPS(NY)0.46
Fwd EY1.49%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.25
OCFY0.82%
SpS9.14
BVpS6.89
TBVpS-2.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.7% | ||
| ROE | -7.26% | ||
| ROCE | 2.86% | ||
| ROIC | 2.26% | ||
| ROICexc | 2.38% | ||
| ROICexgc | 5.55% | ||
| OM | 5.41% | ||
| PM (TTM) | N/A | ||
| GM | 63.94% | ||
| FCFM | N/A |
ROA(3y)-2.68%
ROA(5y)-2.4%
ROE(3y)-7.46%
ROE(5y)-6.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y37.89%
ROICexcg growth 5Y4.3%
ROICexc growth 3Y45.07%
ROICexc growth 5Y7.68%
OM growth 3Y31.35%
OM growth 5Y5.5%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.05%
GM growth 5Y-0.68%
F-Score4
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.08 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 7.08 | ||
| Cap/Depr | 47.24% | ||
| Cap/Sales | 2.88% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 24.03% | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.53 | ||
| Quick Ratio | 3.95 | ||
| Altman-Z | 2.4 |
F-Score4
WACC8.51%
ROIC/WACC0.27
Cap/Depr(3y)42.06%
Cap/Depr(5y)43.23%
Cap/Sales(3y)2.8%
Cap/Sales(5y)3.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-42.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-116.67%
EPS Next Y126.09%
EPS Next 2Y75.18%
EPS Next 3Y52.55%
EPS Next 5Y46.07%
Revenue 1Y (TTM)5.94%
Revenue growth 3Y9.14%
Revenue growth 5Y7.06%
Sales Q2Q%1.59%
Revenue Next Year9.03%
Revenue Next 2Y9.83%
Revenue Next 3Y10.38%
Revenue Next 5Y11.26%
EBIT growth 1Y-9.27%
EBIT growth 3Y43.36%
EBIT growth 5Y12.95%
EBIT Next Year107.33%
EBIT Next 3Y42.09%
EBIT Next 5Y33.37%
FCF growth 1Y97.95%
FCF growth 3YN/A
FCF growth 5Y7.33%
OCF growth 1Y200.63%
OCF growth 3YN/A
OCF growth 5Y7.04%